

Parsippany, New Jersey, June 9th, 2017

FOR IMMEDIATE RELEASE

For more information, contact Michael Cerame, mcerame@extremitymedical.com

Extremity Medical announces the release of BioFuse, a next generation viable cell bone graft.

Extremity Medical, LLC announces the release of its next generation viable cell bone graft for use in the foot, ankle, wrist and hand. This live-cell graft supplies the physiologic and essential components needed for robust bone formation: osteogenic (cells), osteoinductive (biologic stimulants), and an osteoconductive (scaffold). Unlike other currently available live cell bone grafts, BioFuse utilizes proprietary processing advancements focused on providing faster harvesting, and significant reduction in the exposure to harmful stressors that damage cells during processing.

Extremity Medical feels the scientific advancements utilized in the processing of BioFuse vastly improves the health and viability of this graft, significantly increasing both the quantity and quality of the stem cells available per cc.

In addition to more osteogenic potential, in vitro testing also indicates that BioFuse provides higher levels of osteoinductive biologic stimulants, and increased osteoconductivity as compared to traditionally processed live bone cell grafts.

Matt Lyons, Chairman and CEO of Extremity Medical commented, "BioFuse is a next generation viable bone matrix that will have a significant impact on the bone graft market for the extremities. This addition to the growing Extremity Medical portfolio will compliment our current and planned product portfolio for 2017 and beyond and aligns with our continued goal to release innovative products that will significantly impact the extremity surgeon's ability to treat challenging patient conditions."

Extremity Medical, LLC is an orthopedic device company specializing in the development of next generation systems addressing unmet needs for the extremity surgeon